In this paper, we report the design and moleculardocking study of analogues of antimycin A3 as inhibitors of anti-apoptotic Bcl-2 of breast cancer. Twenty designed compounds and the original antimycin A3 were docked based on their interaction with breast tumor receptor binding target Bcl-2. The docking resulted in the five top-ranked compounds, namely, compounds 11, 14, 15, 16, and 20, which have a lower G binding energy, better affinity and stronger hydrogen bonding interactions to the active site of Bcl-2 than antimycin A3. Among those five top-ranked compounds, analogue compounds 11 and 14, which have an 18-membered tetralactone core and 18-membered tetraol core, respectively, exhibited the strongest hydrogen bond interaction, formed high stability conformation, and demonstrated the greatest inhibitory activity on the catalytic site of Bcl-2.
References
[1]
O’Shaughnessy, J. (2005) Extending Survival with Chemotherapy in Metastatic Breast Cancer. The Oncologist, 10, 20-29. http://dx.doi.org/10.1634/theoncologist.10-90003-20
[2]
Lage, H. (2003) Drug Resistance in Breast Cancer. Cancer Therapy, 1, 81-91. http://dx.doi.org/10.1186/bcr2573
[3]
Rivera, E. and Gomez, H. (2010) Chemotheraphy Resistance in Metastatic Breast Cancer: The Evolving Role of Ixabepilone. Breast Cancer Research, 12, S2.
[4]
Ueki, M., Kusumoto, A., Hanafi, M., Shibata, K., Tanaka, T. and Taniguchi, M. (1997) UK-3A, a Novel Antifungal Antibiotics from Streptomyces sp. 517-02. Fermentation, Isolation, Structural Elucidation and Biological Properties. The Journal of Antibiotics, 50, 551-555. http://dx.doi.org/10.7164/antibiotics.50.551
[5]
Han, Y.H., Kim, S.H., Kim, S.Z. and Park, W.H. (2008) Antimycin A as a Mitochondrial Electron Transport Inhibitor Prevents the Growth of Human Lung Cancer A549 Cells. Oncology Reports, 20, 689-693.
http://dx.doi.org/10.3892/or_00000061
[6]
Park, W.H., Han, Y.W., Kim, S.H. and Kim, S.Z. (2007) An ROS Generator, Antimycin A, Inhibits the Growth of HeLa Cells via Apoptosis. Journal of Cellular Biochemistry, 102, 98-109. http://dx.doi.org/10.1002/jcb.21280
[7]
Liu, W., Bulgaru, A., Haigentz, M., Stein, C.A., Perez-Soler, R. and Mani, S. (2003) The Bcl2-Family of Protein Ligands as Cancer Drugs: The Next Generation of Therapeutics. Current Medicinal Chemistry-Anti-Cancer Agents, 3, 217-223. http://dx.doi.org/10.2174/1568011033482459
[8]
Miyoshi, H., Tokutake, N., Imaeda, Y., Akagi, T. and Iwamura, H. (1995) A Model of Antimycin A Binding Based on Structure-Activity Studies of Synthetic Antimycin A Analogue. Biochimica et Biophysica Acta (BBA)—Bioenergetics, 1229, 149-154. http://dx.doi.org/10.1016/0005-2728(94)00185-8
[9]
Pettit, G.R., Smith, T.H., Feng, S., Knight, J.C., Tan, R., Pettit, R.K. and Hinrichs, P.A. (2007) Antineoplastic Agents. 561. Total Synthesis of Respirantin. Journal of Natural Products, 70, 1073-1083. http://dx.doi.org/10.1021/np0680735
[10]
Thomas, G. (2003) Fundamentals of Medicinal Chemistry. John Wiley & Sons Ltd., Chichester.
[11]
Arsianti, A., Tanimoto, H., Morimoto, T., Bahtiar, A., Takeya, T. and Kakiuchi, K. (2012) Synthesis and Anticancer Activity of Polyhydroxylated 18-Membered Analogue of Antimycin A3. Tetrahedron, 68, 2884-2891.
[12]
Vidal, D., Garcia-Serna, R. and Mestres, J. (2011) Chemoinformatics and Computational Chemical Biology. Chemoinformatics and Computational Chemical Biology, 672, 489-502.
http://dx.doi.org/10.1007/978-1-60761-839-3_19
[13]
Wang, Y., Xiao, J., Suzek, T.O., Zhang, J. and Wang, J., et al. (2009) A Public Information System for Analyzing Bio-activities of Small Molecules. Nucleic Acids Research, 37, 1-11. http://dx.doi.org/10.1093/nar/gkp456
[14]
Krüger, D. and Gohlke, H. (2010) DrugScorePPI for Scoring Protein-Protein Interactions: Improving A Knowledge-Based Scoring Function by Atom Type Based QSAR. Journal of Cheminformatics, 2, 1-20.
http://dx.doi.org/10.1186/1758-2946-2-S1-P20
![\"\"](\"Edit_9d852483-7f0b-4307-a8fe-d2447207615c.bmp\")
G binding energy, better affinity and stronger hydrogen bonding interactions to the active site of Bcl-2 than antimycin A3. Among those five top-ranked compounds, analogue compounds 11 and 14, which have an 18-membered tetralactone core and 18-membered tetraol core, respectively, exhibited the strongest hydrogen bond interaction, formed high stability conformation, and demonstrated the greatest inhibitory activity on the catalytic site of Bcl-2.
